Navidea Biopharmaceuticals, Inc. | Ekinops
Update: 2024-07-10
Description
Navidea Biopharmaceuticals, Inc. (OTC: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company’s pivotal NAV3-33 clinical trial. Dr. Michael Blue, Navidea’s Chief Medical Officer, said "Results are not indicative of a commercially viable product.”
Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops technology to launch its new SD-WAN offer named SD-WAN Essentials, transforming Enterprise connectivity into a stepping stone to the Cloud.
For more information, please visit StockDayMedia.com
Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops technology to launch its new SD-WAN offer named SD-WAN Essentials, transforming Enterprise connectivity into a stepping stone to the Cloud.
For more information, please visit StockDayMedia.com
Advertising Inquiries: https://redcircle.com/brands
Privacy & Opt-Out: https://redcircle.com/privacy
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
